Work

Results of First in Human (FIH) Phase 1 Pharmacokinetic (PK) Guided Dose-Escalation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)

Year: 2015

Type: article

Source: Blood

DOI: 10.1182/blood.v126.23.1683.1683

Authors: Michael R. Savona, Olatoyosi Odenike, Philip C. Amrein, David P. Steensma, Wael A. Harb, Amy E. DeZern, Laura C. Michaelis, Stefan Faderl, James N. Lowder, Pietro Taverna, Aram Oganesian, Richa Dua, Roya Nawabi, Mohammad Azab, Guillermo Garcia-Manero

Institutions: Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, University of Chicago, Massachusetts General Hospital, Dana-Farber Cancer Institute, Horizon Oncology Center, Johns Hopkins University, Johns Hopkins Hospital, Medical College of Wisconsin, Hackensack University Medical Center, Astex Pharmaceuticals, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2979947481

FWCI: 1.302

Cites:

Cited by: 8

Related to: 10